According to the World Health Organization (WHO), fungi diseases are becoming increasingly public health concern.

The Global Health Agency recently stated that fungal diseases, including drug-resistant infections such as Candida, are affecting immunocomous patients, such as chemotherapy, living with HIV, or receiving organ transplants.

The WHO warned that effective treatment and lack of limited clinical capabilities, especially in low and medium-or-II countries, are putting millions at risk.

The agency first published the report, exposing the immediate requirement of better drugs and clinical equipment to deal with fungi infections.

Dr. Yukiko Nakani said, “aggressive fungus infection is a threat to the life of the weakest people, but in countries there is a lack of necessary treatments to save life.”

WHO’s fungal priority list of pathogens (FPPL) classifies some fungi as ‘significant priority’ hazards, with more than 88%of the mortality rate.

However, treatment development remains sluggish. Only four new antifungal drugs have been approved in the last decade, and only three candidates are in the final stages of clinical trials, thereby not the possibility of new approval in the near future.

Existing antifungal remedies have significant drawbacks, including severe side effects, drug interactions and prolonged hospitalization.

The report also highlighted the lack of pediatrics and clinical trials for children.

The WHO diagnosis report suggests that current testing for fungi infections is often slow, expensive, and advanced laboratory needs infrastructure, which makes them inaccessible to many, especially in low-resources settings.

To resolve these challenges, who are calling for increased investment in global monitoring, financial incentives for drug development and research in immune-based treatments.

Extending access to inexpensive, rapid clinical devices is also important to improving the initial detection and treatment of fungal diseases.

Since fungus infection becomes more broad and resistant to existing drugs, which emphasize that immediate treatment and clinical differences require immediate action to stop.